ChristophUlrichCorrellMD

Child & Adolescent Psychiatry

Medical Director, Recognition and Prevention (RAP) Program, Department of Psychiatry, The Zucker Hillside Hospital Investigator, Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research Professor, Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine

Join to view full profile

Dr. Correll is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Correll's full profile

Already have an account?

Office
The Zucker Hillside Hospital Dept of Psych
75 59 263RD Street
Glen Oaks, NY 11004
Phone+1 718-470-4812

Education & Training

Zucker School of Medicine at Hofstra/Northwell at Zucker Hillside HospitalFellowship, Child and Adolescent Psychiatry, 2001 - 2003
Free Univ Berlin- Fac MedClass of 1993
Long Island Jewish Medical CenterResidency, Psychiatry

Certifications & Licensure

NY State Medical License 2013 - 2026
American Board of Psychiatry and Neurology Psychiatry
American Board of Psychiatry and Neurology Child & Adolescent Psychiatry

Clinical Trials

Treating Drug-Resistant Childhood Schizophrenia Start of enrollment: 2001 Oct 01
Completed
Phase 4
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms Start of enrollment: 2004 Mar 01
Completed
Not Applicable
Clinical Risk State for Bipolar Disorder in Adolescents Start of enrollment: 2009 Sep 01
Active, not recruiting

Publications & Presentations

PubMed

1 citations
Letter to the Editor Concerning "Glucagon-Like Peptide Agonists for Weight Management in Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis".
Anders Fink-Jensen, Christoph U Correll
Acta Psychiatrica Scandinavica. 2025-04-01
Decreasing prevalence or increase in unregistered cases of bulimia nervosa in children and adolescents in Germany? A comparison using representative claims data pre- v...
Jule Leickert, Stephan Zillmer, Christian J Bachmann, Annika Vivirito, Dirk Enders
Eating and Weight Disorders. 2025-03-21
A Single-Dose, Randomized, Open-Label, Parallel Design Study to Characterize the Pharmacokinetics of an Investigational Olanzapine Intranasal Spray Compared to a Refer...
Stuart Madden, Leslie Citrome, Christoph U Correll, Evelyn K Shih, Miguel Lopez-Toledano
The Journal of Clinical Psychiatry. 2025-03-19

Journal Articles

Association Between Cardiovascular Risk Factors and Cognitive Impairment in People with Schizophrenia
Christoph Correll, MD, JAMA Psychiatry
Effectiveness of Transdiagnostic Cognitive-Behavioral Psychotherapy Compared with Management as Usual for Youth with Common Mental Health Problems
Christoph Correll, MD, JAMA Psychiatry
Impact of Comprehensive Treatment for First Episode Psychosis on Substance Use Outcomes: A Randomized Controlled Trial
Corinne Cather, Robert Rosenheck, Christoph U Correll, Psychiatry Research

Authored Content

Management of Patients with Severe Mental Illness During the Coronavirus Disease 2019 PandemicJune 2020
Management of Patients with Severe Mental Illness During the Coronavirus Disease 2019 PandemicJune 2020
Management of Patients with Severe Mental Illness During the Coronavirus Disease 2019 PandemicJune 2020
Management of Patients with Severe Mental Illness During the Coronavirus Disease 2019 PandemicJune 2020
Join now to see all

Press Mentions

Spinogenix Announces Open Enrollment for Phase 2 US Trial Following FDA Clearance of IND Application for SPG302, the First Synaptic Regenerative Therapy for SchizophreniaMarch 30th, 2025
A Lines of Therapy Analysis Found That Use of UZEDY as a First-Line Treatment Option Was at 12%. However, Patients Prescribed UZEDY Had Most Commonly Received Oral Second-Generation Antipsychotics as Their Initial TherapyNovember 1st, 2024
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (Risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)September 21st, 2024
Join now to see all

Grant Support

Project 4 AcisrNational Institute Of Mental Health2010–2012
Project 1 AcisrNational Institute Of Mental Health2010–2012
Adverse Events Unit (Research Methods Core)National Institute Of Mental Health2010–2012
3/3-Improving Metabolic Parameters Of Antipsychotic Child Treatment (IMPACT)National Institute Of Mental Health2008–2011
Improving Metabolic Parameters Of Antipsychotic Child Treatment (IMPACT)National Center For Research Resources2010
Factors For Metabolic Abnormalities In Children With Psychiatric DisordersNational Center For Research Resources2010
Biological And Genetic Risk Factors For Weight GAIN And Metabolic AbnormalitiesNational Center For Research Resources2007–2008
Biological &Genetic Risk Factors For Anti-Psychotic Induced Weight GAIN &MeNational Center For Research Resources2005–2006
Treating Refractory Childhood SchizophreniaNational Institute Of Mental Health2005